Nyrada banks $12 million as directors contribute in nearly half

Managing Director and Chief Executive James Bonnar said, "This capital raise marks a pivotal moment for Nyrada. The strong support from both new and existing investors is a powerful validation of our science, our team, our novel drug Xolatryp, and our potential to address serious unmet clinical needs." …